Abstract: A system and method for the detection of autoantibodies in saliva is described. In particular, the system is suitable for detecting an autoantibody in a subject, wherein the presence of the autoantibody is indicative of the presence or increased risk of development of an autoimmune disease or disorder.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating myositis. More particularly, the present invention relates to a pharmaceutical composition for preventing or treating myositis, comprising mitochondria as an active ingredient. When the pharmaceutical composition of the present invention comprising exogenous mitochondria as an active ingredient is administered to a subject suffering from myositis, inflammatory cells infiltrated into the muscle cells of the subject can be reduced. In addition, the pharmaceutical composition of the present invention effectively inhibits the expression of IL-1?, TNF-?, and IL-6, inflammatory cytokines. Therefore, the pharmaceutical composition according to the present invention can be usefully used for preventing or treating myositis.

Abstract: A peptide for treating rheumatoid arthritis and use thereof are provided, and a peptide consisting of an amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 3, or SEQ ID NO: 5 or a polynucleotide encoding the same, and a pharmaceutical composition for treating rheumatoid arthritis or a health functional food composition for improving rheumatoid arthritis, each including the peptide, are provided.

Abstract: The present invention relates to a TNF-? (tumor necrosis factor-alpha)/CXCL-10 (C-X-C motif chemokine 10) double targeting antibody based on the IgG format. Specifically, it was verified that an antibody, in which scFv having a heavy chain variable domain and a light chain variable domain of the CXCL10 specific antibody links to the C-terminus of the heavy chain constant domain of the TNF-? specific antibody, is a bispecific antibody that effectively binds to both TNF-? and CXCL10, and thus the antibody can be useful as a double targeting antibody capable of identifying TNF-?/CXCL10. A composition of the present invention comprises a TNF-?/CXCL-10 double targeting antibody which effectively binds to both TNF-? and CXCL10. The double targeting antibody of the present invention has excellent TNF-? inhibitory activity and osteoclast differentiation inhibitory activity compared with the TNF-? or CXCL10 single targeting antibody.

Abstract: The present invention relates to a novel epitope of IP-10 (IFN-?-inducible protein 10), to an antibody to the epitope or an antigen-binding fragment thereof, to a composition comprising the epitope as an active ingredient for inducing an antibody to IP-10, and to a pharmaceutical composition comprising the antibody or the antigen-binding fragment thereof for preventing or treating diseases relating to IP-10. The anti-IP-10 antibody of the present invention can be effectively used in preventing or treating various diseases relating to IP-10 such as multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus.

Abstract: The present invention relates to a TNF-? (tumor necrosis factor-alpha)/CXCL-10 (C-X-C motif chemokine 10) double targeting antibody based on the IgG format. Specifically, it was verified that an antibody, in which scFv having a heavy chain variable domain and a light chain variable domain of the CXCL10 specific antibody links to the C-terminus of the heavy chain constant domain of the TNF-? specific antibody, is a bispecific antibody that effectively binds to both TNF-? and CXCL10, and thus the antibody can be useful as a double targeting antibody capable of identifying TNF-?/CXCL10. A composition of the present invention comprises a TNF-?/CXCL-10 double targeting antibody which effectively binds to both TNF-? and CXCL10. The double targeting antibody of the present invention has excellent TNF-? inhibitory activity and osteoclast differentiation inhibitory activity compared with the TNF-? or CXCL10 single targeting antibody.

Abstract: The present invention relates to a novel epitope of IP-10 (IFN-?-inducible protein 10), to an antibody to the epitope or an antigen-binding fragment thereof, to a composition comprising the epitope as an active ingredient for inducing an antibody to IP-10, and to a pharmaceutical composition comprising the antibody or the antigen-binding fragment thereof for preventing or treating diseases relating to IP-10. The anti-IP-10 antibody of the present invention can be effectively used in preventing or treating various diseases relating to IP-10 such as multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus.

Abstract: The present invention relates to a diagnostic composition for autoimmune diseases, comprising agent measuring a methylation level of CD3Z gene, a diagnostic method and a kit using the same. More particularly, the present invention relates to a composition for diagnosing autoimmune diseases according to the methylation level of CD3Z gene, or additionally ADA or VHL gene, and a method for diagnosing autoimmune diseases by measuring the methylation level. The methylation of any one or more of the ADA, VHL, and CD3Z genes of the present invention is specific to autoimmune diseases, and thus the composition comprising an agent measuring a methylation level of the present invention can be used for the diagnosis of autoimmune diseases.

Abstract: The present invention relates to monoclonal antibodies specifically binding to a membrane antigen of human mesenchymal stem cells, hybridoma cell lines producing the same, and methods for identifying or isolating human mesenchymal stem cells using the same. The monoclonal antibodies of this invention exhibit excellent specificity to human mesenchymal stem cells, inter alia, bone marrow-derived human mesenchymal stem cells, so that it allows for the identification and isolation of human mesenchymal stem cells with much higher specificity.

Abstract: The present invention relates to monoclonal antibodies specifically binding to a membrane antigen of human mesenchymal stem cells, hybridoma cell lines producing the same, and methods for identifying or isolating human mesenchymal stem cells using the same. The monoclonal antibodies of this invention exhibit excellent specificity to human mesenchymal stem cells, inter alia, bone marrow-derived human mesenchymal stem cells, so that it allows for the identification and isolation of human mesenchymal stem cells with much higher specificity.